Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Baran

Advanced Heart Failure and Transplant Cardiology Weston, FL Medical Doctor

NPI 1871594150 CMS profile 130582

2950 Cleveland Clinic Blvd, Weston, FL 33331

Open in the dashboard

General payments

$116,310

260 records reported · program years 2019–2025

Research payments

$4,218

Paid to them · 7 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$318,433 paid to institutions, not to them · program years 2019–2022

Through program year 2025, David Baran of Weston, FL is reported in the CMS Open Payments database as having received $116,310 across 260 general payments and $4,218 in research payments paid to them. Separately, studies naming them as principal investigator received $318,433 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 88th percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,583 36
2025 Research $1,125 1
2024 General $5,890 19
2024 Research $2,250 2
2023 General $10,904 32
2022 General $8,074 31
2021 General $22,786 39
2020 General $9,100 23
2020 Research $843 4
2019 General $50,973 80

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Baran
  • Advanced Heart Failure and Transplant Cardiology median
  • Middle half of Advanced Heart Failure and Transplant Cardiology
  • National median

In program year 2025, general payments to David Baran were reported at $8,583. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.

Show as a table
Year David Baran Advanced Heart Failure and Transplant Cardiology median Middle half National median
2019 $50,973 $863 $224–$4,562 $163
2020 $9,100 $452 $122–$3,992 $114
2021 $22,786 $550 $159–$3,571 $132
2022 $8,074 $729 $221–$4,357 $149
2023 $10,904 $1,002 $309–$5,827 $160
2024 $5,890 $931 $273–$5,204 $164
2025 $8,583 $1,024 $289–$6,890 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. LivaNova USA, Inc. $23,617 29 payments
  2. Pfizer Inc. $15,606 9 payments
  3. Novartis Pharmaceuticals Corporation $11,928 9 payments
  4. Maquet Cardiovascular U.S. Sales, L.L.C. $11,147 11 payments
  5. Abbott Laboratories $7,940 76 payments
  6. Alnylam Pharmaceuticals Inc. $6,747 11 payments
  7. Arrow International, Inc. $6,289 2 payments
  8. Michigan Critical Care Consultants, Inc. $5,425 2 payments
  9. Abiomed $4,541 31 payments
  10. Impulse Dynamics (USA) Inc. $3,698 9 payments
  11. Other $19,372 71 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $60,612 28 payments
  2. Consulting Fee $25,854 13 payments
  3. Food and Beverage $14,977 188 payments
  4. Travel and Lodging $11,459 28 payments
  5. Honoraria $3,400 2 payments
  6. Education $8 1 payment
Products named General payments · program years 2019–2025
  1. VYNDAQEL $15,606 9 payments
  2. TandemLife $14,115 15 payments
  3. ENTRESTO $11,928 9 payments
  4. LifeSPARC System $7,606 7 payments
  5. ONPATTRO $6,747 11 payments
  6. MANTA $6,289 2 payments
  7. CARDIOSAVE $6,215 6 payments
  8. Crescent cannula $5,425 2 payments
  9. Soft Flow cannula $5,425 2 payments
  10. CARDIOSAVE HYBRID, TYPE B PLUG $4,296 6 payments
  11. Other $33,325 182 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. XVIVO Perfusion Inc. $3,375 3 payments
  2. TransMedics, Inc. $843 4 payments

Prescribing to Medicare patients

Part D · data year 2024 · 52 drugs

Part D claims

3,186

Median for Advanced Heart Failure and Transplant Cardiology: 1,489

Drug cost

$1,197,409

Median for Advanced Heart Failure and Transplant Cardiology: $885,869

Branded share of claims

31.9%

Median for Advanced Heart Failure and Transplant Cardiology: 32.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entresto Sacubitril/Valsartan Brand 337 $476,384
Jardiance Empagliflozin Brand 272 $324,013
Eliquis Apixaban Brand 163 $207,273
Farxiga Dapagliflozin Propanediol Brand 48 $61,324
Xarelto Rivaroxaban Brand 32 $42,368
Ozempic Semaglutide Brand 13 $14,610
Repatha Sureclick Evolocumab Brand 16 $14,209
Tacrolimus Generic 39 $8,973
Eplerenone Generic 52 $5,830
Mycophenolate Mofetil Generic 27 $5,012

The 10 drugs with the highest cost, of 52 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 800 Part D prescribers listed as Advanced Heart Failure and Transplant Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$105,113

Medicare's payments for the services billed

Medicare patients

259

Average age 71

Services billed

1,175

84 women, 175 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 64%
Chronic kidney disease 64%
Atrial fibrillation 61%
Arthritis 47%
Diabetes 46%
COPD 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UPTRAVI
  • Actelion Pharmaceuticals US, Inc. $34
$34 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

267 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Advanced Heart Failure and Transplant Cardiology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record